KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Financing Activities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Cash from Financing Activities for 13 consecutive years, with $113.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 836.0% to $113.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $117.1 million, a 865.48% increase, with the full-year FY2025 number at $117.1 million, up 865.48% from a year prior.
  • Cash from Financing Activities was $113.5 million for Q4 2025 at Xenon Pharmaceuticals, up from $2.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $324.0 million in Q4 2023 to a low of $6000.0 in Q4 2022.
  • A 5-year average of $84.2 million and a median of $6.3 million in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 100.0% in 2022, then skyrocketed 5400133.33% in 2023.
  • Xenon Pharmaceuticals' Cash from Financing Activities stood at $324.0 million in 2021, then crashed by 100.0% to $6000.0 in 2022, then surged by 5400133.33% to $324.0 million in 2023, then crashed by 96.26% to $12.1 million in 2024, then soared by 836.0% to $113.5 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Cash from Financing Activities are $113.5 million (Q4 2025), $2.4 million (Q3 2025), and $65000.0 (Q2 2025).